Regardless of the cause of a disease, most diseases involve gene dysregulation. Omega Therapeutics is developing a new class of programmable, epigenomic, mRNA medicines designed to make specific epigenetic changes and correct abnormal gene expression to treat or cure diseases. We spoke to Mahesh Karande, president and CEO of Omega Therapeutics, about its pipeline of mRNA therapies, how they work, and its recently announced collaboration with Novo Nordisk to develop an epigenomic controller to treat obesity.
Delivering Oxygen to Tissue in Need
Using Gene Therapy to Create a Drug Biofactory within a Patient
Finding New Uses for TNF Inhibitors
Using AI to Map the Undiscovered World of Bioactive Compounds in Plants
Improving the Delivery of Drugs through Thin Film Freezing
Using CRISPR to Target RNA Instead of DNA
An Antisense Pioneer Brings Custom Treatments to Patients with Ultra-Rare Conditions
Managing Neurodegenerative Diseases with Better Data to Improve Outcomes
A Small Molecule Cancer Drug That Promotes an Adaptive Immune Response
Sloan-Kettering Spin-Out Harnesses AI to Diagnose Cancer
Bringing Innovation to Cell and Gene Therapy Manufacturing
Tapping Psychedelics for their Anti-Inflammatory Powers
Advancing Cell Therapies Beyond Cancer
How the Pandemic Transformed a Small Diagnostics Company
Eliminating Security, Privacy, and Regulatory Burdens with Synthetic Data
Using Computational Discovery to Build Better Immunotherapies
The Year in Biotech and What’s Ahead in 2021
Bringing Precision Cancer Care to Dogs
As COVID-19 Vaccines Ship, One Company Brings Innovation to the Vials
Advancing an Antibody to Prevent and Treat Cytokine Storms in COVID-19
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Ground Truths